OGL
osteoporose associada à gestação e lactação
Palavras-chave:
Osteoporose, gestação, lactação, fraturas vertebrais, romosozumabeResumo
A fratura por osteoporose associada à gestação e à lactação é um evento raro e de etiologia não estabelecida, até o momento. Ocorre mais comumente no terceiro trimestre da gestação ou no primeiro trimestre do período de amamentação, sendo a coluna o local mais afetado, nos seguimentos dorsal e lombar, podendo ocorrer na pelve, com menor incidência. Será apresentado caso clínico de fratura osteoporótica idiopática multissegmentar de coluna torácica e lombar em lactante, onde foi instituído, após a parada da amamentação, tratamento com anticorpo monoclonal humanizado, romosozumabe.
Referências
Qian Y, Wang L, Yu L, Huang W. Pregnancy – and lactation – associated osteoporosis with vertebral fractures: a systematic review.
Vanhouten J N, Wysolmerski J J. Low estrogen anda high parathyroid hormone – related peptide levels contribute to accelerated bone resorption and bone loss in lactatin mice. Encocrinology 144(12): 5521-5529
Winter E M, Ireland A, Butterfield N C, Haffner-Luntzer M, Horcajada M-N, Veldhuis-Vlug A G, Oei L, Colaiannig G, Bonnet N. Pregnancy and lactation, a challenge for the skeleton. Endocrine connections, 9:6, R143-R157.
Salari P, Abdollahi M. Influence of pregnancy and lactation on maternal bone health: a systematic review. Journal of Family and reproductive health, Vol. 8, Nº 4, December 2014.
Ijuin A, Yoshikata H, Asano R, Tsuburai T, Kikuchi R, Skakibara H. Teriparatide and e denosumab treatment for pregnancy and lactation – associated osteoporosis with multiple vertebral fractures: a case study. Taiwanese Journal of Obstetrics & Gynecology, 56 (2017) 863-866.
Willems D, Javaid M K, Pinedo-Villanueva R, Libanati C, Yehoshua A, Charokopou M. Importance of time point-specific indirect treatment comparisons of osteoporosis treatments: a systematic literature review and network meta-analyses. Clinical therapeutics, Vol. 44, nº 1, 2022.
Lewiecki EM, Dinavahi RV, Lazaretti-Castro M, et al. One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the frame extension study. J Bone Miner Res. 2019;34(3):419-28.
Ominsky MS, Boyd SK, Varela A, et al. Romosozumab improves bone mass and strength while maintaining bone quality in ovariectomized cynomolgus monkeys. J Bone Miner Res. 2017; 32:788-801.
McClung MR, Brown JP, Diez-Perez A, et al. Effects of 24 Months of treatment with romosozumab followed by 12 Months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study. J Bone Miner Res. 2018; 33(8):1397-406.
